A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
Status:
Terminated
Trial end date:
2017-03-13
Target enrollment:
Participant gender:
Summary
ALM201/0001 is a Phase I, open-label, dose-escalation study of the safety, tolerability and
pharmacokinetics (PK) of ALM201.
Part 1 will be a dose-escalation study. Patients with advanced solid tumours will receive
daily doses of ALM201 on Days 1-5, 8-12 and 15-19 in 21 day cycles.
Part 2 will be a dose-expansion of the Maximum Tolerated Dose (MTD) determined in Part 1.
Patients with advanced ovarian cancer will be enrolled with the main objective to determine
the recommended Phase II dose.